- Home
- SRAD vs ADPT Comparison
SRAD vs ADPT Comparison
Compare SRAD & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRAD | ADPT |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.5B |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SRAD | ADPT |
|---|---|---|
| Price | $11.95 | $26.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 8 |
| Target Price | $17.98 | ★ $30.21 |
| AVG Volume (30 Days) | 1.5M | ★ 2.0M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,976,000.00 |
| Revenue This Year | $17.61 | $5.03 |
| Revenue Next Year | $11.06 | $22.97 |
| P/E Ratio | $49.48 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $11.39 | $12.00 |
| 52 Week High | $26.18 | $30.74 |
Technical Indicators
Market Signals| Indicator | SRAD | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 46.13 | 51.10 |
| Support Level | $11.74 | $23.76 |
| Resistance Level | $13.36 | $30.35 |
| Average True Range (ATR) | 0.56 | 1.48 |
| MACD | 0.04 | 0.25 |
| Stochastic Oscillator | 40.07 | 53.35 |
Price Performance
Historical ComparisonAbout SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.